SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Information, marketing, and pricing in the U.S. antiulcer drug market.
2 references·16 citing·52 second hop
Information, marketing, and pricing in the U.S. antiulcer drug market. (1995)Information, marketing, and pricing in th…Market Share Rewards to Pioneering Brands: An Empirical Analysis and Strategic Implications (1986)Market Share Rewards to Pione…The economics of advertising (1972)The economics of advertisingAsk Your Doctor? Direct-to-Consumer Advertising of Pharmaceuticals (2018)Ask Your Doctor? Direct-to-Co…Managing Revenue across Retail Channels: The Interplay of Service Performance and Direct Marketing (2014)Managing Revenue across Retai…Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry (2011)Regulation and Welfare: Evide…Determinants of branded prescription medicine prices in OECD countries (2011)Determinants of branded presc…Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field (2009)Marketing of the Life Science…Performance effects of imitative entry (2008)Performance effects of imitat…The Adoption of Innovations by Provider Organizations in Health Care (2007)The Adoption of Innovations b…Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration (2007)Strategic Entry Deterrence an…Generic Competition in the US Pharmaceutical Industry (2006)Generic Competition in the US…Direct to consumer advertising in pharmaceutical markets (2005)Direct to consumer advertisin…A Simple Model of Pharmaceutical Price Dynamics (2003)A Simple Model of Pharmaceuti…Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales (2002)Deregulating Direct‐to‐Consum…Second-Mover Advantages in Dynamic Quality Competition (2001)Second-Mover Advantages in Dy…Moral hazard in physician prescription behavior (2000)Moral hazard in physician pre…Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs (2000)Consumption Externalities and…Chapter 25 The pharmaceutical industry (2000)Chapter 25 The pharmaceutical…The Iron Cage Revisited: Institutional Isomorphism and Collective Rationality in Organizational Fields (1983)Economic Action and Social Structure: The Problem of Embeddedness (1985)Initial Test of a Principle-Guided Approach to Transdiagnostic Psychotherapy With Children and Adolescents (2016)Cooperative innovation through a talent management pool: A qualitative study on coopetition in healthcare (2017)Practitioner Review: Empirical evolution of youth psychotherapy toward transdiagnostic approaches (2017)Diffusion of Innovations 1 (2019)A Computationally Efficient Quadrature Procedure for the One-Factor Multinomial Probit Model (1982)The economics of moral hazard: comment (1982)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing (2003)Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan (2008)Physician Agency and Adoption of Generic Pharmaceuticals (2012)Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy (1986)Asset Stock Accumulation and Sustainability of Competitive Advantage (1989)Absorptive Capacity: A New Perspective on Learning and Innovation (1990)Competitive Landscape Shifts: The Influence of Strategic Entrepreneurship on Shifts in Market Commonality (2018)Developing compositional capability in emerging-market SMEs (2020)Knowledge mobilization in the face of imitation: Microfoundations of knowledge aggregation and firm‐level innovation (2020)Good News and Bad News: Representation Theorems and Applications (1981)The Theory of Industrial Organization (1988)Theory of Industrial Organization. (1989)The Relative Importance of Actual and Potential Competition: Empirical Evidence From the Pharmaceuticals Market (2003)Games Hospitals Play: Entry Deterrence in Hospital Procedure Markets (2005)Competition in Health Care Markets11We wish to thank participants at the Handbook of Health Economics meeting in Lisbon, Portugal, Pedro Pita Barros, Rein Halbersman, and Cory Capps for helpful comments and suggestions. Misja Mikkers, Rein Halbersma, and Ramsis Croes of the Netherlands Healthcare Authority graciously provided data on hospital and insurance market structure in the Netherlands. David Emmons kindly provided aggregates of the American Medical Association's calculations of health insurance market structure. Leemore Dafny was kind enough to share her measures of market concentration for the large employer segment of the US health insurance market. All opinions expressed here and any errors are the sole responsibility of the authors. No endorsement or approval by any other individuals or institutions is implied or should be inferred. (2011)What do we know about entry? (1995)Generic Entry and the Pricing of Pharmaceuticals (1997)Pharmaceutical pricing policies in a global market (2008)Balancing Innovation and Access: Patent Challenges Tip the Scales (2009)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)An Information Processing Theory of Consumer Choice (1979)Imitation Costs and Patents: An Empirical Study (1981)The theory and practice of econometrics (1986)Status quo bias in decision making (1988)Strategic Orientation of the Firm and New Product Performance (1997)Self-efficacy mechanism in human agency. (1982)A Conceptual Model of Service Quality and Its Implications for Future Research (1985)Evolving to a New Dominant Logic for Marketing (2003)Drivers of Sales Performance: A Contemporary Meta-Analysis (2010)Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development (2013)International new ventures: rapid internationalization across different industry contexts (2014)A New Product Growth for Model Consumer Durables (1969)Patent Statistics as Economic Indicators: A Survey (1990)A Simple Model of Herd Behavior (1992)An empirical model of learning and patient spillovers in new drug entry (2003)First-mover advantages (1988)First-mover (dis)advantages: retrospective and link with the resource-based view (1998)Innovation timing games: a general framework with applications (2004)Timing of technology adoption and product market competition (2010)Measuring the impact of corporate social responsibility practices on brand equity in the banking industry in Bangladesh (2018)Why Do Corporations Give to Charity? (1988)Caveat Emptor: The Construction of Nonprofit Consumer Watchdog Organizations (1998)Evaluating the Potential of Interactive Media through a New Lens: Search versus Experience Goods (1998)
this work references cited by second hop

References

  • 1986Market Share Rewards to Pioneering Brands: An Empirical Analysis and Strategic Implications569 cited
  • 1972The economics of advertising389 cited

Cited by

  • 2000Moral hazard in physician prescription behavior164 cited
  • 2007The Adoption of Innovations by Provider Organizations in Health Care160 cited
  • 2009Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field159 cited
  • 2000Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs152 cited
  • 2006Generic Competition in the US Pharmaceutical Industry145 cited
  • 2001Second-Mover Advantages in Dynamic Quality Competition134 cited
  • 2008Performance effects of imitative entry121 cited
  • 2007Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration118 cited
  • 2011Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry96 cited
  • 2018Ask Your Doctor? Direct-to-Consumer Advertising of Pharmaceuticals91 cited
  • 2002Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales91 cited
  • 2003A Simple Model of Pharmaceutical Price Dynamics83 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2005Direct to consumer advertising in pharmaceutical markets83 cited
  • 2011Determinants of branded prescription medicine prices in OECD countries77 cited
  • 2000Chapter 25 The pharmaceutical industry76 cited
  • 2014Managing Revenue across Retail Channels: The Interplay of Service Performance and Direct Marketing45 cited